Evolution of Biological Bandages as First Cover for Burn Patients.

Détails

Ressource 1Télécharger: wound.2019.1037.pdf (874.10 [Ko])
Etat: Public
Version: de l'auteur
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_BC7604AFE085
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Evolution of Biological Bandages as First Cover for Burn Patients.
Périodique
Advances in wound care
Auteur(s)
Abdel-Sayed P., Hirt-Burri N., de Buys Roessingh A., Raffoul W., Applegate L.A.
ISSN
2162-1918 (Print)
ISSN-L
2162-1918
Statut éditorial
Publié
Date de publication
01/11/2019
Peer-reviewed
Oui
Volume
8
Numéro
11
Pages
555-564
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Significance: Cutaneous wound regeneration is vital to keep skin functions and for large wounds, to maintain human survival. In a deep burn, the ability of the skin to heal is compromised due to the damage of vasculature and resident cells, hindering a coordinated response in the regeneration process. Temporal skin substitutes used as first cover can play a major role in skin regeneration as they allow a rapid wound covering that, in turn, can significantly reduce infection risk, rate of secondary corrective surgeries, and indirectly hospitalization time and costs. Recent Advances: Skin was one of the first tissues to be bioengineered providing thus a skin equivalent; however, what is the current status subsequent to 40 years of tissue engineering? We review the classic paradigms of biological skin substitutes used as first cover and evaluate recent discoveries and clinical approaches adapted for burn injuries cover, with an emphasis on innovative cell-based approaches. Critical Issues: Cell-based first covers offer promising perspectives as they can have an active function in wound healing, such as faster healing minimizing scar formation and prepared wound bed for subsequent grafting. However, cell-based therapies encounter some limitations due to regulatory hurdles, as they are considered as "Advanced Therapy Medicinal Products," which imposes the same industry-destined good manufacturing practices as for pharmaceutical products and biological drug development. Future Directions: Further improvements in clinical outcome can be expected principally with the use of cell-based therapies; however, hospital exemptions are necessary to assure accessibility to the patient and safety without hindering advances in therapies.
Mots-clé
Critical Care and Intensive Care Medicine, Emergency Medicine, biological bandages, first cover, skin graft, temporary substitute
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/09/2019 10:36
Dernière modification de la notice
06/09/2020 6:23
Données d'usage